Meet our Management

Robert Wessman

CHAIRMAN AND CEO
Portrait of Robert Wessman
Actavis CEO and key strategist 1999 to 2008

Under Wessman‘s leadership Actavis became a leading force in the generic pharmaceutical industry. He changed the company from a small local industry player to the 4th largest global generic company operating in 55 countries.

Alvogen Executive Chairman and CEO 2009-currently

As founder and CEO, Wessman has led Alvogen from being a small US based contract manufacturing business to becoming a top 15 global generics player operating in 35 countries in only six years. Alvogen has received multiple industry recognitions including CPhI Company of the Year Awards and multiple service awards. Development of a balanced yet specialized portfolio consisting of 500 marketed products, as well as a deep pipeline of high-value products in development, is at the core of Wessman’s strategy enabling Alvogen to proactively respond to market needs and fuel sustainable and profitable growth.

Alvotech Founder and Chairman

Alvotech is Biopharmaceutical Company with fully integrated R&D, API and fill and finish capabilities with a brand new state-of-the art facilities. Alvotech has 6 biosimilars in the pipeline with the first product launches scheduled in 2019 at patent expiry.

Operational experience and record growth

Companies led by Wessman have a collective CAGR of more than 60 percent. He has led over 50 strategic acquisitions and partnerships and established operations in over 60 countries around the globe. These companies have achieved very strong organic growth in combination with external growth.

Wessman’s achievements have made him the subject of two Harvard Business School Case Studies, titled “Robert Wessman and the Actavis Winning Formula” (2008) and “Alvogen” (2015).

Alvogen Americas Senior Management

Lisa Graver

President of Alvogen America
Portrait of Lisa Graver

Lisa Graver is the President for the Americas region. Lisa, who joined Alvogen in 2010, has served as EVP of Strategic Operations in the U.S. market for the last three years. In this role she has overseen global R&D and regulatory affairs, portfolio selection, and legal for the U.S.  Under her leadership, Alvogen has built a pipeline 28 potential first-to-file/first-to-market drugs for the U.S. market and a total pipeline of over 60 ANDA‘s. 

Prior to joining Alvogen, Lisa served as Vice President of Intellectual Property for Actavis. She received her JD, cum laude, from Case Western University and Honors Bachelor of Science degree from Lakehead University.



William Hill

EVP – US Commercial Operations
Portrait of William Hill

William Hill brings 25 years of brand and generic pharmaceuticals experience in roles of increasing responsibility that includes multiple therapeutic areas and all classes of trade. Mr. Hill comes to Alvogen from Dr. Reddy’s Laboratories, where he led North American sales and commercial operations. He was promoted to VP Sales after a successful tenure in National Accounts, highlighted by several Paragraph 4 product launches and Dr. Reddy’s entry into the top ten generic company status. 

Prior to Dr. Reddy’s, Mr. Hill served in sales and management roles URL, Dey, Warner Chilcott, Endo and Sandoz.

Bill is married (wife Christy) and resides with his three children (Quentin 13, Jaden 11, Maya 9) in Lake Norman, NC.

Andrea Johnson

Vice President - Sales Operations
Portrait of Andrea Johnson

Andrea Johnson has more than 20 years’ experience in both generic and branded pharmaceuticals. Her knowledge and experience in Customer Focus, Operational Effectiveness, Teambuilding and Process Improvements (Kaizen and Lean Six Sigma) allows her to effectively lead and manage Alvogen’s customer service, credit & collections and contracting & pricing operations.

Prior to joining Alvogen, Mrs. Johnson was the Senior Director of Pricing & Contracts and Financial Sales Operations at Actavis Inc., where she was able to successfully lead significant operational improvements resulting in millions of dollars in savings.

Mrs. Johnson has held roles of increasing responsibility throughout her career including successful positions at Johnson & Johnson Healthcare Systems, Pfizer and Alpharma.

Dr. Mayank Joshi

Vice Precident - Research and Development
Portrait of Dr. Mayank Joshi

Dr. Mayank Joshi, Vice President of Research and Development, leads both internal and external scientific development teams responsible for ensuring successful execution of product development, product transfers, scale-up, process engineering, facility and equipment qualification and all validation tasks to support revenue and profitability growth for Alvogen's US organization. He is also driving the development of first to file ANDAs in the development pipeline, and conducting technical due diligence for potential third party partners identified by business development.

Dr Joshi has extensive experience of about 20 years in the development and commercialization of modified release products. Prior to joining Alvogen in 2012, Dr. Joshi was Director Formulations (R&D) at Actavis (Watson Inc), Senior Manager of Full Formulation Development at Apotex Inc, and Group Leader at Alembic, among other roles. Dr. Joshi has a Ph.D. in Novel Drug Delivery Systems from the Maharaja Sayajirao University of Baroda, India. He has been principal inventor of numerous patents and have published several scientific papers in respected journals around the world.

Entrepreneur Of The Year

Alvogen has been honored by Ernst & Young for rethinking the ways businesses grow and thrive.

ernst&young